Key result
Rivaroxaban is currently the subject of safety concerns and debate following investigations into the ROCKET-AF trial used for its regulatory approvals.
This article examines the ongoing debate and investigations regarding the safety of rivaroxaban following the ROCKET-AF trial.
Rivaroxaban has been somewhat of a buzzword, particularly since it has received approvals from European regulators. However, investigations into the ROCKET-AF trial, used to gain these approvals both in the USA and Europe, have raised questions about its safety. Ben Sneath examines the drug and the debate that currently surrounds its use
No takes yet. Share an insight, caveat, or question.
Ben Sneath (2016) studied this question. Rivaroxaban is currently the subject of safety concerns and debate following investigations into the ROCKET-AF trial used for its regulatory approvals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: